Sangamo Therapeutics Faces Legal Scrutiny Following Partnership Termination

The Law Offices of Howard G. Smith have announced an investigation into Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) SGMO regarding potential violations of federal securities laws that may have affected investors.

Investors with Losses Should Take Action

If you are an investor who has suffered a loss in Sangamo Therapeutics, Inc. (SGMO), reach out to the Law Offices of Howard G. Smith to learn about possible claims to recover your losses.

To discuss your legal rights, you can contact the Law Offices of Howard G. Smith via email at howardsmith@howardsmithlaw.com, by phone at (215) 638-4847, or visit our website at www.howardsmithlaw.com.

Recent Developments

On December 30, 2024, after market hours, Sangamo announced that Pfizer Inc. (“Pfizer”) had ended its partnership to develop a hemophilia A gene therapy product.

Following this announcement, Sangamo’s stock plummeted by $1.32, or 56.4%, closing at $1.02 per share on December 31, 2024, severely affecting investor value.

Get in Touch to Learn More

If you purchased Sangamo securities, have relevant information, or wish to know more about these claims, please reach out to us:

Law Offices of Howard G. Smith,

3070 Bristol Pike, Suite 112,

Bensalem, Pennsylvania 19020,

Telephone: (215) 638-4847

Email: howardsmith@howardsmithlaw.com,

Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in certain jurisdictions based on applicable laws and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250102552804/en/